Danicopan for hemoglobinuria, paroxysmal

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 May 2022: Trial registered, NCT05389449
  2. 28 Oct 2022: Trial started, NCT05389449

The trials

NCT05389449: A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

State
Under way
Phase
Phase 3
People
80 taking part
Started
28 Oct 2022
Primary completion
24 Aug 2026
Arms
Danicopan
Results
None posted
  1. 25 May 2022: Trial registered
  2. 28 Oct 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Voydeya.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.